The investigators sought to describe HRQOL and treatment satisfaction of ibrutinib-treated patients with CLL in the real-world setting.
Given the difficulty in definitevely diagnosing acute promyelocytic leukemia, researchers sought to develop a rapid point of care diagnostic assay.
Patients with a NPM1, IDH1, IDH2, or DNMT3A mutation had a complete response or complete response with incomplete hematologic recovery rate of more than 80%.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
Induction regimen FLAG+/-Ida appears to be more effective than 7+3 in patients with non-favorable risk AML, but prospective data are needed.
Patients with acute myeloid leukemia with myelodysplasia-related changes diagnosed on the basis of dysplasia reported improved overall and event-free survival.
The development of a second hematologic malignancy after being diagnosed with chronic lymphocytic leukemia (CLL) appears to be uncommon, a retrospective study found.
Because lead-lined rooms are not always available, the SIERRA trial sought to establish whether mobile shields could provide a suitable alternative for reducing exposure rates.
Researchers summarized risk factors for relapse in acute myeloid leukemia, as well as current and prospective treatment strategies for minimizing relapse risk.
Researchers found that mutated EGR2 and TP53 were significantly associated with worse progression-free survival in patients with chronic lymphocytic leukemia.
A study found that grading systems for assessing toxicities from CAR-T therapy produced inconsistent scores, prompting a call for a more unified grading approach.
Researchers assessed the cytogenetic characteristics of coagulopathy in patients with molecularly distinct acute leukemias.
Continued investigation of Richter transformation may be warranted as new CLL treatments emerge.
Researchers reported long-term follow-up results from the phase 3 RERISE study, which assessed the efficacy of radotinib compared with imatinib for CML treatment.
Risk of a leukemia diagnosis was found to be highest between 3 to 6 years following manifestation of symptoms associated with dengue viral infection.
Researchers assessed whether the incremental cost per quality-adjusted life-year of tisagenlecleucel matched estimated willingness-to-pay thresholds.
Machine learning may help identify newly diagnosed patients with CLL who are at risk for infection or treatment within 2 years of a diagnosis.
Relative survival rates were found to improve for all patient age groups over time, although excess mortality persisted to some degree.
Researchers hypothesized that imbalances of toxic and essential metals in patients with acute myeloid leukemia may be associated with poorer survival.
Patients who were treatment-naive had an overall response rate of 95%, while patients with relapsed/refractory disease had an overall response rate of 92%.
Researchers assessed whether adjusted asparaginase dosage helps reduce toxicity while maintaining sufficient asparaginase depletion in children with ALL.
Mutations were found in 70% of patients, with 53% of patients possessing driver mutations and 17 genes showing mutations in more than 2% of patients.
It’s useful to be aware of misconceptions your patients might have about leukemia. We debunk 6 common myths.
Four-year cumulative risk of any relapse lower for dasatinib in the context of intensive chemotherapy
For the entire cohort of pediatric patients with standard-risk acute lymphoblastic leukemia, overall survival at 6 years was greater than 95%.
Median progression-free survival was 34.2 months in patients who received ofatumumab and 16.9 months in patients who received no additional treatment.
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
The analysis revealed that Medicare beneficiaries had different treatment outcomes compared with the trial participants.
Improvement in median overall survival from 5.8 years in 1995 to 2011 to not reached in 2009 to 2017.
Risk score identifies risk among patients with acute leukemia treated with anthracyclines before chemo
Although prolonged periods of neutropenia are common following induction and intensification of chemotherapy, this study showed that pediatric patients with AML can be safely managed in the outpatient setting after resolution of neutropenia.
Induction therapy with blinatumomab did not appear to confer a survival benefit, though undergoing stem cell transplant did.
Eligibility criteria for this study included intermediate- or high-risk cytogenetics, and CR or CR with incomplete count recovery following induction chemotherapy.
There is an increasing focus on using the achievement of undetectable MRD in bone marrow as a clinical trial end point in patients with CLL.
Older age, body mass index above 30, and development of drug-induced diabetes mellitus were associated with increased risk for type 2 diabetes mellitus.
Among patients treated with an acute lymphoblastic leukemia induction regimen, 72% achieved end-of-induction complete remission.
This study addressed the dearth of information on the incidence of psychiatric disorders related to corticosteroid-containing treatment in patients with hematologic malignancies.
Researchers sought to determine if nonmyeloablative HSCT conditioning was noninferior to myeloablative approaches in more vulnerable patients with AML.
Patients receiving ibrutinib for chronic lymphocytic leukemia experienced an average weight gain of 2.4 kg at 1 year after therapy initiation.
Patients with acute myeloid leukemia and myelodysplastic syndromes reported similar quality of life irrespective of the conditioning regimen the received.
In patients with complete response at transplant, age was found to be the only predictor of clinical outcomes.
This study investigated whether T-cell gene-expression profiles and other molecular characteristics of T-cell populations were associated with CAR-T performance.
Exercise tolerance was found to be associated with verbal fluency, dominant motor speed, and math academics, among other neurocognitive metrics.
Central nervous system relapse rates in pediatric acute lymphoblastic leukemia can be reduced with additional early doses of intrathecal chemotherapy.
Researchers assessed whether high platelet counts in pediatric patients with chronic myeloid leukemia resulted in thrombosis or bleeding.
Patients receiving treosulfan and fludarabine experienced improved event-free and overall survival compared with patients receiving busulfan and fludarabine.